Core Viewpoint - Fuhong Hanlin (02696) announced a significant breakthrough in the treatment of gastric cancer with its self-developed PD-1 inhibitor, Hanshu (Surulimumab), achieving predefined efficacy standards in a Phase III clinical trial, leading to a nearly 6% increase in stock price [1] Company Summary - Fuhong Hanlin's PD-1 inhibitor, Hanshu, combined with chemotherapy, has become the first treatment globally to replace postoperative adjuvant chemotherapy with immunotherapy in the perioperative setting for gastric cancer [1] - The company plans to expedite the application for market approval for this indication following the positive trial results [1] - CEO Dr. Zhu Jun emphasized the company's commitment to gastrointestinal tumors as a core area and the intention to accelerate the translation of research results to benefit patients [1]
港股异动 | 复宏汉霖(02696)午后涨近6% H药胃癌围术期III期研究达终点 公司拟提前申报该适应症上市